Xie Jie, Jones Thomas J, Feng Dongni, Cook Todd G, Jester Andrea A, Yi Ru, Jawed Yameena T, Babbey Clifford, March Keith L, Murphy Michael P
Cell Transplant. 2017 Feb 16;26(2):173-189. doi: 10.3727/096368916X692212. Epub 2016 Jul 18.
Abdominal aortic aneurysm (AAA) is a potentially lethal disease associated with immune activation-induced aortic degradation. We hypothesized that xenotransplantation of human adipose-derived stem cells (hADSCs) would reduce aortic inflammation and attenuate expansion in a murine AAA model. Modulatory effects of ADSCs on immune cell subtypes associated with AAA progression were investigated using human peripheral blood mononuclear cells (hPBMNCs) cocultured with ADSCs. Murine AAA was induced through elastase application to the abdominal aorta in C57BL/6 mice. ADSCs were administered intravenously, and aortic changes were determined by ultrasonography and videomicrometry. Circulating monocytes, aortic neutrophils, CD28- T cells, FoxP3+ regulatory T cells (Tregs), and CD206+ M2 macrophages were assessed at multiple terminal time points. In vitro, ADSCs induced M2 macrophage and Treg phenotypes while inhibiting neutrophil transmigration and lymphocyte activation without cellular contact. Intravenous ADSC delivery reduced aneurysmal expansion starting from day 4 [from baseline: 54.8% (saline) vs. 16.9% (ADSCs), n = 10 at baseline, n = 4 at day 4, p < 0.001], and the therapeutic effect persists through day 14 (from baseline: 64.1% saline vs. 24.6% ADSCs, n = 4, p < 0.01). ADSC administration increased aortic Tregs by 20-fold (n = 5, p < 0.01), while decreasing CD4+CD28- (-28%), CD8+CD28- T cells (-61%), and Ly6G/C+ neutrophils (-43%, n = 5, p < 0.05). Circulating CD115+CXCR1-LY6C+-activated monocytes decreased in the ADSC-treated group by day 7 (-60%, n = 10, p < 0.05), paralleled by an increase in aortic CD206+ M2 macrophages by 2.4-fold (n = 5, p < 0.05). Intravenously injected ADSCs transiently engrafted in the lung on day 1 without aortic engraftment at any time point. In conclusion, ADSCs exhibit pleiotropic immunomodulatory effects in vitro as well as in vivo during the development of AAA. The temporal evolution of these effects systemically as well as in aortic tissue suggests that ADSCs induce a sequence of anti-inflammatory cellular events mediated by paracrine factors, which leads to amelioration of AAA progression.
腹主动脉瘤(AAA)是一种与免疫激活诱导的主动脉降解相关的潜在致命疾病。我们假设,人脂肪来源干细胞(hADSCs)的异种移植将减轻小鼠AAA模型中的主动脉炎症并减弱主动脉扩张。使用与ADSCs共培养的人外周血单核细胞(hPBMNCs)研究了ADSCs对与AAA进展相关的免疫细胞亚型的调节作用。通过向C57BL/6小鼠的腹主动脉应用弹性蛋白酶诱导小鼠AAA。静脉内给予ADSCs,并通过超声检查和视频显微镜测定主动脉变化。在多个终末时间点评估循环单核细胞、主动脉中性粒细胞、CD28-T细胞、FoxP3+调节性T细胞(Tregs)和CD206+ M2巨噬细胞。在体外,ADSCs诱导M2巨噬细胞和Treg表型,同时在无细胞接触的情况下抑制中性粒细胞迁移和淋巴细胞激活。从第4天开始,静脉内给予ADSCs可减少动脉瘤扩张[相对于基线:生理盐水组为54.8%,ADSCs组为16.9%,基线时n = 10,第4天时n = 4,p < 0.001],并且治疗效果持续至第14天(相对于基线:生理盐水组为64.1%,ADSCs组为24.6%,n = 4,p < 0.01)。给予ADSCs使主动脉Tregs增加20倍(n = 5,p < 0.01),同时使CD4+CD28-(-28%)、CD8+CD28-T细胞(-61%)和Ly6G/C+中性粒细胞减少(-43%,n = 5,p < 0.05)。在ADSC治疗组中,循环CD115+CXCR1-LY6C+激活的单核细胞在第7天时减少(-60%,n = 10,p < 0.05),与此同时主动脉CD206+ M2巨噬细胞增加2.4倍(n = 5,p < 0.05)。静脉注射的ADSCs在第1天短暂植入肺中,在任何时间点均未植入主动脉。总之,在AAA发展过程中,ADSCs在体外和体内均表现出多效性免疫调节作用。这些作用在全身以及主动脉组织中的时间演变表明,ADSCs诱导了一系列由旁分泌因子介导的抗炎细胞事件,从而导致AAA进展得到改善。